Search

Your search keyword '"Giavazzi R."' showing total 542 results

Search Constraints

Start Over You searched for: Author "Giavazzi R." Remove constraint Author: "Giavazzi R."
542 results on '"Giavazzi R."'

Search Results

1. Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness

2. BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models

5. The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

6. Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts (British Journal of Cancer, (2022), 126, 1, (120-128), 10.1038/s41416-021-01609-1)

7. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

8. Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities

9. Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells

11. L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling

12. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases

15. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

16. The next generation PARP inhibitor AZD5305 is active in a broad range of pre-clinical models of ovarian cancer

20. Soluble stroma-related biomarkers of pancreatic cancer

21. A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data

25. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab

33. Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging

34. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts

35. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab

37. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations

41. Metastatic Potential of Metastases, Tumor Cell Heterogeneity, and Therapeutic Implications

43. Phosphorylation and Alternative Splicing of MEF2C, a Dual Switch Function in Muscle Regeneration

44. Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors: AN INTEGRATED STRATEGY FOR THE DEVELOPMENT OF NEW ANTIANGIOGENIC COMPOUNDS*

45. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts

46. TrypsinogenIV, a new player in tumor angiogenesis

48. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts

Catalog

Books, media, physical & digital resources